Browse the latest research summaries in the field of endocrinology for spinal cord injury patients and caregivers.
Showing 11-20 of 211 results
Frontiers in Cell and Developmental Biology, 2023 • August 25, 2023
This review discusses the potential of melatonin as a natural antioxidant therapy for spinal cord injury (SCI). It highlights the relationship between melatonin rhythm and SCI, the neuroprotective rol...
KEY FINDING: Melatonin maintains the integrity of the blood–spinal cord barrier (BSCB), reducing edema and neutrophil infiltration after traumatic SCI.
Frontiers in Endocrinology, 2023 • August 24, 2023
The editorial emphasizes the increasing prevalence of sarcopenia, osteosarcopenia, and sarcopenic obesity due to the aging global population and advancements in healthcare. It highlights the importanc...
KEY FINDING: Fasting insulin combined with the aspartate aminotransferase to alanine aminotransferase (AST/ALT) ratio are appropriate predictors of sarcopenia.
Endocrinol Metab, 2023 • December 1, 2023
This study compared bone mineral density (BMD) in middle-aged men with spinal cord injury (SCI) to community-dwelling men, finding lower hip BMD in the SCI group. Paraplegia and motor-incomplete SCI w...
KEY FINDING: Men with SCI had significantly lower bone mineral density in the hip region compared to community-dwelling men, but lumbar spine T-scores did not differ significantly.
Mayo Clin Proc Inn Qual Out, 2023 • October 1, 2023
The study compared the incidence of serious and life-threatening morbidities among adults with traumatic spinal cord injury (TSCI) with and without type 2 diabetes (T2D). Adults living with TSCI and T...
KEY FINDING: Adults with TSCI and T2D had a higher incidence of all assessed morbidities compared to those with TSCI alone.
Frontiers in Endocrinology, 2023 • November 6, 2023
This editorial summarizes findings from a research topic focused on (osteo)sarcopenia and sarcopenic obesity, highlighting the relationship between sarcopenia and various comorbidities such as obesity...
KEY FINDING: Obesity is a risk factor for sarcopenia, with a positive relationship between skeletal muscle mass and absolute fat mass but a negative association with appendicular fat mass.
Top Spinal Cord Inj Rehabil, 2023 • July 1, 2023
This study investigated the effects of salsalate on fasting and postprandial glycemic, lipidemic, and inflammatory responses in persons with tetraplegia. The main findings were that salsalate signific...
KEY FINDING: Salsalate significantly reduced fasting and postprandial glucose values in persons with tetraplegia.
Spinal Cord, 2024 • April 1, 2024
This retrospective longitudinal cohort study examined the effect of the level of spinal cord injury (SCI) on the incidence of diabetes mellitus (DM) and mortality in a cohort of veterans. The study fo...
KEY FINDING: The risk of DM development over the 21-year follow-up period did not differ significantly between those with tetraplegia (TP) and paraplegia (PP).
Physiological Reports, 2024 • May 20, 2024
This study validated existing BMR prediction equations in individuals with SCI, focusing on innervated and denervated subgroups, and examined differences between predicted and measured BMR in females ...
KEY FINDING: SCI-specific equations by Chun et al., Nightingale & Gorgey, and AB-specific FFM equations accurately predicted BMR for innervated males.
JBMR Plus, 2024 • June 7, 2024
One year of romosozumab treatment in women with chronic SCI increased DXA-derived aBMD at the lumbar spine and hip. These results were congruent with CT results at the hip, which indicated increases i...
KEY FINDING: After 12 mo of treatment, areal BMD at the lumbar spine and total hip were significantly increased with median changes of 10.2% (IQR: 8.3–15.2%, p<.001) and 4.2% (IQR: 3.4–7.7%, p = .009), respectively.
Obes Sci Pract, 2024 • July 23, 2024
This study explores health care providers' (HCPs) views about barriers to AOM use in persons living with SCI/D. HCPs described four main thematic barriers to AOM use in persons with SCI/D: (1) AOM sid...
KEY FINDING: HCPs identified AOM side effects (bowel problems, gastrointestinal distress, skin breakdown, muscle loss) as significant barriers due to potential exacerbation in SCI/D patients.